



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Jan Voorberg,
✉ j.voorberg@sanquin.nl

[†]These authors have contributed equally to this work

RECEIVED 06 October 2025
REVISED 16 October 2025
ACCEPTED 17 October 2025
PUBLISHED 07 November 2025

CITATION
Barracclough A, Bär I, van Duijl T, Fijnvandraat K, Eikenboom JCJ, Leebeek FWG, Bierings R, Voorberg J and Trasanidou D (2025) Correction: Rewriting the script: gene therapy and genome editing for von Willebrand Disease. *Front. Genome Ed.* 7:1719330. doi: 10.3389/fgeed.2025.1719330

COPYRIGHT
© 2025 Barracclough, Bär, van Duijl, Fijnvandraat, Eikenboom, Leebeek, Bierings, Voorberg and Trasanidou. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Rewriting the script: gene therapy and genome editing for von Willebrand Disease

Alastair Barracclough^{1†}, Isabel Bär^{2†}, Tirsia van Duijl³, Karin Fijnvandraat¹, Jeroen C. J. Eikenboom⁴, Frank W. G. Leebeek², Ruben Bierings², Jan Voorberg^{3*} and Despoina Trasanidou^{3†}

¹Department of Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, ²Department of Hematology, Erasmus University Medical Centre, Rotterdam, Netherlands, ³Molecular Hematology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁴Division of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Centre, Leiden, Netherlands

KEYWORDS

gene therapy, VWD, endothelial cells, delivery, CRISPR-Cas, *in vivo* delivery

A Correction on Rewriting the script: gene therapy and genome editing for von Willebrand Disease

by Barracclough A, Bär I, van Duijl T, Fijnvandraat K, Eikenboom JCJ, Leebeek FWG, Bierings R, Voorberg J and Trasanidou D (2025). *Front. Genome Ed.* 7:1620438. doi: 10.3389/fgeed.2025.1620438

There was a mistake in the caption of Figure 1 as published. The legend of Figure 1 included text from an older version of the figure, which should have been removed. The incorrect caption read: Overview of von Willebrand Disease sub-types, von Willbrand Factor (VWF) domains, and variant distributions. (A) Summary of von Willebrand Disease sub-types (A) Von Willebrand Factor domains and binding sites. (B) Distribution and frequency of von Willebrand Factor variants curated in the Leiden Open Variation Database (LOVD) (Accessed and data retrieved on 8-1-2025). Created in BioRender.

The corrected caption of Figure 1 appears below.

Overview of von Willbrand Factor (VWF) domains, and variant distributions. (A) Von Willebrand Factor domains and binding sites. (B) Distribution and frequency of von Willebrand Factor variants curated in the Leiden Open Variation Database (LOVD) (Accessed and data retrieved on 8-1-2025). Created in BioRender.

The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.